Budd-Chiari syndrome (BCS) · Many patients with BCS harbour several prothrombotic disorders. · Liver disease blurs the diagnostic features of most prothrombotic disorders. · Myeloproliferative disease account for 50% of BCS patients. Their recognition largely relies on the assessment of V617F JAK2 mutation in peripheral blood. · Treatment for BCS consists of the successive implementation of anticoagulation, percutaneous angioplasty, transjugular intrahepatic shunt and last, liver transplantation. · Using this progressive treatment strategy, overall 5-year survival rates approaching 90% are currently achieved. Veno-occlusive disease/Sinusoidal obstruction syndrome (VOD/SOS) · VOD/SOS is produced by a toxic injury to sinusoidal endothelial cells. · Many chemotherapeutic agents can induce VOD/SOS. · Knowledge in the metabolic determinants of drug toxicity to sinusoidal endothelium has deepened. The translation of new knowledge into prevention and treatment of VOD/SOS still need clinical studies. · Reduced intensity myeloablative regimens have proved efficient in reducing the incidence of VOD/SOS.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.